Centro de Tecidos Biológicos de Minas Gerais, Fundação Hemominas, Lagoa Santa, Minas Gerais, Brazil.
Transfusion. 2021 Apr;61(4):1202-1214. doi: 10.1111/trf.16289. Epub 2021 Feb 10.
The kinetics of hematopoietic recovery after autologous stem cell transplantation (ASCT) may be affected by laboratory procedures. The aim of this study was to evaluate the influence of characteristics of the cryopreserved units of peripheral blood stem cells (PBSC) on postthawing cell viability and engraftment outcomes after ASCT.
This was a retrospective cohort study including individuals referred for ASCT. Cryopreservation was conducted at a single processing facility between 2014 and 2019, and patients received clinical care at six transplant centers. Covariates and outcome data were retrieved from participants' records.
The study population comprised 619 patients (345 [55.7%] male). Median age was 53 years. Multiple myeloma was the most common diagnosis (62.7%). Higher preapheresis CD34+ cell count, lower nucleated cell (NC) concentration per cryobag, and composition of the cryoprotectant solution (5% dimethyl sulfoxide [DMSO] and 6% hydroxyethyl starch) were statistically significantly associated with higher postthawing cell viability. The linear regression model for time to neutrophil and platelet engraftment included the infused CD34+ cell dose and the composition of the cryoprotectant solution. Patients who had PBSC cryopreserved using 10% DMSO solution presented six times higher odds (odds ratio [OR] = 6.9; 95% confidence interval [CI]: 2.2-21.1; p = .001) of delayed neutrophil engraftment (>14 days) and two times higher odds (OR = 2.3, 95%CI: 1.4-3.7; p = .001) of prolonged hospitalization (>18 days).
The study showed that mobilization efficacy, NC concentration, and the composition of the cryoprotectant solution significantly affected postthawing cell viability. In addition, the composition of the cryoprotectant solution significantly impacted engraftment outcomes and time of hospitalization after ASCT.
自体造血干细胞移植(ASCT)后造血恢复的动力学可能受到实验室程序的影响。本研究旨在评估外周血造血干细胞(PBSC)冷冻保存单位的特征对 ASCT 后解冻后细胞活力和植入结果的影响。
这是一项回顾性队列研究,包括接受 ASCT 的个体。2014 年至 2019 年间,在一个单一的处理设施中进行冷冻保存,患者在六个移植中心接受临床护理。从参与者的记录中检索协变量和结果数据。
研究人群包括 619 名患者(345 名[55.7%]男性)。中位年龄为 53 岁。多发性骨髓瘤是最常见的诊断(62.7%)。较高的预处理 CD34+细胞计数、每袋冷冻保存的核细胞(NC)浓度较低以及冷冻保护剂溶液的组成(5%二甲基亚砜[DMSO]和 6%羟乙基淀粉)与解冻后细胞活力较高相关。中性粒细胞和血小板植入的线性回归模型包括输注的 CD34+细胞剂量和冷冻保护剂溶液的组成。使用 10%DMSO 溶液冷冻保存 PBSC 的患者,中性粒细胞植入延迟(>14 天)的可能性高出六倍(优势比[OR] = 6.9;95%置信区间[CI]:2.2-21.1;p =.001),住院时间延长(>18 天)的可能性高出两倍(OR = 2.3,95%CI:1.4-3.7;p =.001)。
该研究表明,动员效率、NC 浓度和冷冻保护剂溶液的组成显著影响解冻后细胞活力。此外,冷冻保护剂溶液的组成对 ASCT 后植入结果和住院时间有显著影响。